Alzheimer's Disease and Exosomes and extracellular vesicles: what the trial registry contains

Why this is studied in Alzheimer's Disease

Alzheimer's involves amyloid and tau pathology, synaptic loss and chronic neuroinflammation years before diagnosis. Cell and exosome approaches target the inflammatory and trophic side rather than removing plaques. The hard problem is delivery across the blood-brain barrier and the fact that by the time symptoms are obvious, substantial neuronal loss has already happened.

What exosomes means in this table

Exosome and extracellular-vesicle products are cell-free: vesicles harvested from cultured cells and given without the cells themselves. They are attractive commercially because they avoid live-cell logistics, and they are regulatorily contested for the same reason — several regulators have issued explicit warnings about unapproved exosome products marketed for human use.

The numbers

Every figure below comes from one reproducible query (alzheimer disease x exosome) run against ClinicalTrials.gov API v2 on 2026-08-29.

How mature is this evidence?

This remains early-stage territory: 10 registered records, none labelled Phase 3 or 4, and 1 currently recruiting.

Completion status: 2 completed, 0 stopped early (0% of all records). A registration is a plan, not a result.

Median planned enrolment is 58 participants (largest single study: 500). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.

Where the studies are

Sites are spread across 5 countries, with China accounting for roughly 56% of country mentions — geography reflects where regulators permit this work and where sponsors sit, not where care is best.

Legal pathway differs by country — see where cell therapy is legal, by country.

Who runs them

Funding profile: 5 academic or hospital sponsors against 2 commercial ones — academic overall, which is worth knowing before reading any single positive report.

• Xuanwu Hospital, Beijing — 2 records
• Ruijin Hospital — 1 record
• Helse Stavanger HF — 1 record
• Shanghai Mental Health Center — 1 record
• Shanghai 10th People's Hospital — 1 record
• Central Hospital, Nancy, France — 1 record

Representative registered studies

Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.

What this page does and does not tell you

None of these numbers say the therapy works. They say how much organised research exists and how far along it is; effect sizes live in published results, not registry entries.

If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.

Frequently asked

How many exosomes studies for Alzheimer's Disease are recruiting right now?

1 of 10 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.

Is exosomes an approved treatment for Alzheimer's Disease?

Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 10 registered studies tell you research exists, not that a product cleared review.

How advanced is the research on exosomes for Alzheimer's Disease?

0 of 10 records carry a Phase 3 or Phase 4 label and 2 are marked completed. Registrations run from 2014 to 2026.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.